Short-term Clinical Experience on Interferon gamma-1b Therapy for Idiopathic Pulmonary Fibrosis.

Hwang, Jung Hye; Chung, Man Pyo; Kang, Eun Hae; Kim, Kyung Chan; Lee, Byoung Hoon; Koh, Won Jung; Suh, Gee Young; Kim, Hojoong; Lee, Kyung Soo; Han, Joungho; Kwon, O Jung

doi:2004.56.6.619

Tuberc Respir Dis > Volume 56(6); 2004 > Article

Original Article

Tuberculosis and Respiratory Diseases 2004;56(6):619-627.
DOI: https://doi.org/10.4046/trd.2004.56.6.619 Published online June 1, 2004.

Short-term Clinical Experience on Interferon gamma-1b Therapy for Idiopathic Pulmonary Fibrosis.

Jung Hye Hwang, Man Pyo Chung, Eun Hae Kang, Kyung Chan Kim, Byoung Hoon Lee, Won Jung Koh, Gee Young Suh, Hojoong Kim, Kyung Soo Lee, Joungho Han, O Jung Kwon

¹Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. mpchung@smc.samsung.co.kr
²Department of Radiology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
³Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

Abstract

BACKGROUND
Corticosteroids in combination with cytotoxic drugs are the mainstays of therapy for idiopathic pulmonary fibrosis (IPF). However, there has been no regimen showing any survival benefit. The aim of this study was to describe a short-term clinical experience on interferon gamma-1b (IFN-gamma1b) therapy for IPF, as an antifibrotic agent. METHODS: Medical records of 27 patients who were treated with IFN-gamma1b (2 million IU, 3 times a week, subcutaneous injection) were retrospectively reviewed. Treatment response was assessed using ATS/ERS criteria in 17 patients who received IFN-gamma1b for more than 6 months. In addition, we compared the efficacy of IFN-gamma1b therapy with that of cyclophosphamide+/-prednisolone therapy (n=26). RESULTS: The median age of IFN-gamma treated group (M:F=19:8) was 59 years (44-74 years). Compared to the patients who showed a stable response at 6 months (n=12), the deteriorated group (n=5) had worse baseline lung function (FVC, 55.4+/-11.3% vs. 70.7+/-10.9%, p=0.019; DLco, 50.3+/-7.3% vs. 76.9+/-19.6%, p=0.014). Lower baseline PaO2 on room air breathing was observed in the deteriorated group (68.6+/-7.8mmHg vs. 91.4+/-6.6mmHg p=0.001). Subcutaneous IFN-gamma1b did not show better efficacy than prednisolone. Five patients discontinued IFN-gamma because of severe side effects. ARDS developed in one patient, who eventually died. CONCLUSION: The administration of IFN-gamma1b is not desirable for patients diagnosed with IPF with poor lung function. Long-term and large-scaled clinical studies are needed for its efficacy in IPF.

Key Words: Pulmonary fibrosis, Usual interstitial pneumonia, Interferon-gamma

TOOLS

METRICS

0 Crossref
Scopus
1,868 View
12 Download

Related articles

Diagnostic Approaches for Idiopathic Pulmonary Fibrosis2024 January;87(1)

Clinical Experience of Short-Course Chemotherapy for Pulmonary Tuberculosis1981 December;28(4)

Short Course Chemotherapy for Pulmonary Tuberculosis1980 September;27(3)

Controlled Clinical Trials of Intermittent Chemotherapy of Pulmonary Tuberculosis1974 June;21(2)

The Clinical Effect of Rifampicin for Retreatment Cases for Pulmonary Tuberculosis1972 June;19(2)

ABOUT

ARTICLE & TOPICS

Article category

Browse all articles >

Topics

Browse all articles >

BROWSE ARTICLES

FOR CONTRIBUTORS

Editorial Office: 101-605, 58, Banpo-daero, Seocho-gu (Seocho-dong, Seocho Art-Xi), Seoul 06652, Korea
Tel: +82-2-575-3825, +82-2-576-5347 Fax: +82-2-572-6683 E-mail: katrdsubmit@lungkorea.org